BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28019639)

  • 1. Novobiocin Analogs as Potential Anticancer Agents.
    Dlugosz A; Janecka A
    Mini Rev Med Chem; 2017; 17(9):728-733. PubMed ID: 28019639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.
    Audisio D; Methy-Gonnot D; Radanyi C; Renoir JM; Denis S; Sauvage F; Vergnaud-Gauduchon J; Brion JD; Messaoudi S; Alami M
    Eur J Med Chem; 2014 Aug; 83():498-507. PubMed ID: 24992077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novobiocin Analogues That Inhibit the MAPK Pathway.
    Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
    J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
    Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
    Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
    Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
    J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
    Kusuma BR; Duerfeldt AS; Blagg BS
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
    Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
    Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
    Peterson LB; Blagg BS
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3957-60. PubMed ID: 20570149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.
    Zhao H; Donnelly AC; Kusuma BR; Brandt GE; Brown D; Rajewski RA; Vielhauer G; Holzbeierlein J; Cohen MS; Blagg BS
    J Med Chem; 2011 Jun; 54(11):3839-53. PubMed ID: 21553822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
    Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
    J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibitors identified from a library of novobiocin analogues.
    Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
    J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
    Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
    Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.
    Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK
    J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
    Marcu MG; Schulte TW; Neckers L
    J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
    Montoir D; Barillé-Nion S; Tonnerre A; Juin P; Duflos M; Bazin MA
    Eur J Med Chem; 2016 Aug; 119():17-33. PubMed ID: 27153346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
    Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.
    Mays JR; Hill SA; Moyers JT; Blagg BS
    Bioorg Med Chem; 2010 Jan; 18(1):249-66. PubMed ID: 19932969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
    Marcu MG; Chadli A; Bouhouche I; Catelli M; Neckers LM
    J Biol Chem; 2000 Nov; 275(47):37181-6. PubMed ID: 10945979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.
    Donnelly AC; Mays JR; Burlison JA; Nelson JT; Vielhauer G; Holzbeierlein J; Blagg BS
    J Org Chem; 2008 Nov; 73(22):8901-20. PubMed ID: 18939877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.